multiple inhalers on a white background Researchers explored the association between dry powder inhaler technique errors and exacerbations and health status in patients with COPD. Severe COPD ...

inhaler use Does teaching proper technique for inhaler use to COPD and asthma patients measurably affect their health outcomes? A dedicated inhaler technique optimization service for hospitalized ...

How to step up asthma treatment in a child who can't use a dry powder inhaler (DPI) licensed for Maintenance and Reliever ...

Dry Powder Inhalers: A Double Win for COPD and Environment By Dennis Thompson HealthDay ReporterTUESDAY, Feb. 24, 2026 (HealthDay News) — Dry powder inhalers might provide a double benefit for people ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...

New long-acting muscarinic antagonist-long-acting beta agonist users had a decreased risk for a first moderate/severe COPD ...

Please provide your email address to receive an email when new articles are posted on . “Many health care systems are discussing a transition to dry-powder inhalers that have a lower carbon footprint ...

Switching asthma patients from a pressurised metered dose inhaler (pMDI) to a dry powder inhaler (DPI) for maintenance therapy more than halves their carbon footprint without loss of asthma control, ...

Flovent, a popular corticosteroid inhaler used to treat asthma, is no longer available. The global manufacturer, Glaxo Smith Kline (GSK), announced in May that the medications — Flovent HFA, a metered ...

Researchers in the United Kingdom compared the potential impact on carbon footprint and asthma symptom control of switching maintenance therapy to a dry powder inhaler vs continuing with a metered ...

Researchers conducted an observational study using real‑world data to compare the effectiveness and safety of initiating three fixed‑dose long‑acting muscarinic antagonist (LAMA)-long‑acting beta‑2 ...